Tolvaptan, an oral vasopressin V2 receptor antagonist, is the only vaptan approved by the European Medicines Agency (EMA) for the treatment of adult patients with HN secondary to SIADH in 2009 [11]. The gene discussed is AVPR2; the disease is inappropriate ADH syndrome.